Aug. 12 at 11:22 AM
$TCRX TScan Therapeutics (Nasdaq: TCRX) reported Q2 2025 financial results and provided updates on its TCR-T therapy programs. The company reported revenue of
$3.1 million and a net loss of
$37.0 million. Key developments include plans to dose first solid tumor patients with multiplex TCR-T in Q3 2025 and present two-year relapse data from the ALLOHA™ Phase 1 heme trial by year-end.
The company's cash position stands at
$218.0 million, expected to fund operations into Q1 2027. TScan plans to initiate a registrational trial for TSC-101 in H2 2025 and file an IND for TSC-102-A0301. Initial safety and response data from the PLEXI-T trial is expected in Q1 2026.
